Randomized Trial Cisplatinum-Cyclophosphamide with and without Induction Interferon Alpha-2b in Treatment of the Advanced Epithelial Ovarian Cancer

Abstract

Objective To compare the efficacy of cisplatinum-cyclophosphamide with and without induction interferon-alpha-2b in the treatment of the advanced epithelial ovarian cancer.

Subjects One hundred and twenty-seven patients of the epithelial ovarian cancer stage III-IV from 5 centers were recruited between August 1992 - November 1995.

Main outcome measure Response rate, drug toxicites, recurrent rate and survival.

Results One hundred and seven evaluable patients included in the study, achieved complete response 51.92% and partial response 19.23% of interferon induction arm (arm-A), compared with 50.90% and 12.72% of without interferon induction (arm-B) respectively (P > 0.05). The pathological complete response revealed 47.82% of arm-A and 55.00% of arm-B (P >0.05), the recurrence occured 27.27% of arm-A and 45.45% of arm-B respectively (P >0.05). The median survival time was 17.00 months (95% CI, 4.93 - 29.07) of arm-A and 17.00 months (95 % CI, 11.75 -22.25) of arm-B. The haematologic toxicity and nephrotoxicity showed higher incidence in arm-A (P < 0.05)